Categories: News

Stellaromics Establishes First U.S. Pyxa™ 3D Spatial Transcriptomics Site at UC Irvine

Renowned vision researcher Dr. Rui Chen to apply 3D spatial multi-omics for mapping sensory systems and advancing Human Cell Atlas discoveries

BOSTON, Dec. 3, 2025 /PRNewswire/ — Stellaromics, a pioneer in 3D spatial biology, today announced the installation of its first U.S.-based Pyxa™ system at the University of California, Irvine (UCI). This milestone marks a significant expansion of Stellaromics’ global beta testing program and follows the inaugural deployment of Pyxa at the University of Glasgow in October 2025.

The system is in the laboratory of Dr. Rui Chen, Professor of Ophthalmology at the Gavin Herbert Eye Institute, Robert M. Brunson Center for Translational Vision Research. Internationally recognized for his work mapping the molecular foundations of human sensory systems, Dr. Chen and his colleagues play a leading role in the Human Cell Atlas initiative, spearheading the Complete Human Eye Atlas to map the eye at single-cell resolution. They are leveraging Pyxa to construct comprehensive 3D spatial atlases of the human eye and trigeminal ganglion, to better understand sensory processing in health and disease.

“The UC Irvine installation marks an important step for Stellaromics as we expand the reach of 3D spatial biology in the United States,” said Todd Dickinson, PhD, CEO of Stellaromics. “Building on our initial deployment in Glasgow, Dr. Chen’s pioneering research in sensory system mapping and cell atlassing exemplifies our mission to reveal the full complexity of tissue biology with the Pyxa platform.”

Designed to deliver high-resolution, multiplexed 3D spatial transcriptomics in intact tissue sections up to 100 µm thick, Pyxa preserves native tissue architecture and spatial context across multiple cellular layers. By capturing subcellular detail for hundreds of molecular targets simultaneously, the system enables researchers to map cell–cell interactions, molecular gradients, and complex tissue structures that underpin biological processes in both health and disease.

About Stellaromics

Stellaromics is a privately held company dedicated to pioneering breakthroughs in 3D spatial multi-omics. The company’s mission is to empower researchers with cutting-edge tools that illuminate the complexities of biological systems, enabling groundbreaking discoveries that improve human health. Stellaromics is headquartered in Boston, Massachusetts, USA.

Media Contact

Kristen White
Co-Founder & Partner, Oak Street Communications
kristen@oakstreetcommunications.com
415.608.6060

View original content to download multimedia:https://www.prnewswire.com/news-releases/stellaromics-establishes-first-us-pyxa-3d-spatial-transcriptomics-site-at-uc-irvine-302631255.html

SOURCE Stellaromics

Staff

Recent Posts

Kanazawa University research: High-speed AFM imaging reveals how brain enzyme forms dodecameric ring structure

KANAZAWA, Japan, Dec. 26, 2025 /PRNewswire/ -- Scientists at the Nano Life Science Institute (WPI-NanoLSI), Kanazawa…

2 hours ago

Arspura Showcases a New Standard for Healthy Kitchen Living at CES 2026

LOS ANGELES, Dec. 25, 2025 /PRNewswire/ -- From January 6–9, 2026, visitors can experience Arspura's…

8 hours ago

XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

RAMAT GAN, ISRAEL, Dec. 24, 2025 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the…

17 hours ago

Relapse Risk Increases During the Holidays; Desert Hope Treatment Center Urges Early Support

LAS VEGAS, Dec. 24, 2025 (GLOBE NEWSWIRE) -- This holiday season, addiction experts at Desert Hope…

17 hours ago

Profound Medical Corp. Announces Upsize of Private Placement

TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the…

17 hours ago